Musculoskeletal Metastasis from Primary Rectal Cancer: Series of Two Cases of a Very Rare Occurrence with a Short Literature Review
- 27 Downloads
As per Globacan 2012, colorectal cancer is the fourth most common cancer afflicting the worldwide population. It is estimated that around 50–60% of all colorectal malignancies will develop metastasis [1, 2] with the liver and lung being the most common sites for such metastasis. Less commonly involved sites include the peritoneum, and rarely involvement of bone, brain, and spleen is seen . Metastatic cancer deposits in skeletal muscles are extremely rare from the gastrointestinal tract and despite a rigorous search of published literature, only 16 case reports of skeletal metastasis from colorectal cancers were found with only five of them originating from the rectum . The management is not clearly defined in such a scenario and the prognosis remains guarded.
A 24-year-old male presented to this hospital with complaints of bleeding per rectum for the past 2 months. He gave history of having undergone a hemorrhoidectomy 3 months previously for...
We would like to acknowledge the Departments of Pathology, Radiology, and Nuclear Medicine at Command Hospital (SC), Pune, for their support.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 4.Ünsal D, Üner A, Simsek A, Üzüm N, Akmansu M. Metastatic rectal adenocarcinoma to forearm muscle: an unusual site of metastasis. Turk J Cancer. 2005;35:181–5.Google Scholar
- 6.de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808–15.CrossRefGoogle Scholar
- 11.Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.CrossRefGoogle Scholar
- 17.Khattak MA, Martin HL, Beeke C, Price T, Carruthers S, Kim S, et al. Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer. 2012;11:247–54.CrossRefGoogle Scholar